Journal of Applied Physiology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


J Appl Physiol (November 26, 2008). doi:10.1152/japplphysiol.91075.2008
This Article
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
106/3/774    most recent
91075.2008v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aljuri, N.
Right arrow Articles by Freitag, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aljuri, N.
Right arrow Articles by Freitag, L.
Submitted on August 10, 2008
Revised on November 12, 2008
Accepted on November 21, 2008

Validation and pilot clinical study of a new bronchoscopic method to measure collateral ventilation prior to endobronchial lung volume reduction

Nikolai Aljuri1* and Lutz Freitag

1 Harvard-MIT

* To whom correspondence should be addressed. E-mail: nikko{at}rodneyperkins.com.

Endobronchial Lung Volume Reduction (ELVR) may be helpful in a selected group of patients with advanced stages of emphysema. However, collateral ventilation (CV) from adjacent lobes through collateral channels often prevents target lobe atelectasis, which presumably mediates clinical responses after ELVR. With the goal of identifying patients who are more or less likely to benefit, we propose Endobronchial Collateral Ventilation Assessment (ECVA), a novel catheter-based endobronchial approach, to quantitatively determine the resistance of collateral channels (Rcoll). ECVA relies on the measurement of spontaneous air flow from the sealed and isolated target compartment during spontaneous respiration in an awake subject, thereby providing a direct, simple and minimally invasive method of assessing Rcoll in lungs. In this study, we validated ECVA in a controlled laboratory setup and tested ECVA's clinical feasibility in 11 emphysematous human subjects undergoing ELVR treatment. To evaluate ECVA in a controlled laboratory setup with known CV levels, we built a benchtop model mimicking a simple one-compartment model of the lungs during temporary compartmental occlusion and spontaneous respiration, which could be adapted to hold restrictors of different sizes representing collateral airways, and applied ECVA to estimate the resistance of various benchtop model restrictors. We then rated ECVA's performance by direct comparison between estimated and actual restrictor resistance and found a correlation coefficient near one. To test ECVA's clinical performance, post-ELVR radiologic assessments were made to determine the occurrence of atelectasis in the treated lobe and inter-lobar Rcoll was estimated in the target lobe via ECVA pre-ELVR. ECVA could be completed in all patients with no adverse events and a high Rcoll by ECVA predicted absorption atelectasis following ELVR (p=0.005). We believe that ECVA may be helpful to distinguish those patients with and without inter-lobar CV by identifying the critical value of Rcoll above which atelectasis is likely to occur.




This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
H. E. Fessler
Collateral damage assessment for endobronchial lung volume reduction
J Appl Physiol, March 1, 2009; 106(3): 755 - 756.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1948 by the American Physiological Society.